Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer- guidance (TA707)

Nivolumab is recommended for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.

National Institute for Health and Care Excellence